Viking Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
VKTX$28.99+8.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $26,676 | $55,516 |
| Short-term investments – available-for-sale | 875,936 | 306,563 |
| Prepaid clinical trial and preclinical study costs | 3,476 | 2,624 |
| Prepaid expenses and other current assets | 1,128 | 2,522 |
| Total current assets | 907,216 | 367,225 |
| Right-of-use assets | 1,003 | 1,126 |
| Deferred financing costs | 56 | 106 |
| Deposits | 46 | 33 |
| Total assets | $908,321 | $368,490 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $9,813 | $7,512 |
| Other accrued liabilities | 17,111 | 11,299 |
| Lease liability, current | 489 | 324 |
| Total current liabilities | 27,413 | 19,135 |
| Lease liability, net of current portion | 630 | 936 |
| Total long-term liabilities | 630 | 936 |
| Total liabilities | 28,043 | 20,071 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2024 and 2023; 111,573,519 shares issued and outstanding at December 31, 2024 and 100,113,770 shares issued and outstanding at December 31, 2023 | 1 | 1 |
| Treasury stock at cost, no shares at December 31, 2024 and 2,193,251 shares at December 31, 2023 | — | (6,795) |
| Additional paid-in capital | 1,368,972 | 733,546 |
| Accumulated deficit | (487,907) | (377,944) |
| Accumulated other comprehensive loss | (788) | (389) |
| Total stockholders’ equity | 880,278 | 348,419 |
| Total liabilities and stockholders’ equity | $908,321 | $368,490 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.